7 (0.2) 0.6 (0.4) 0.32    24 h post-sugery 1.7 (0.2) 1.8 (0.2) 0.82    Intra-operative BE (mmol/l) 0.3 (0.4) 0.4

(0.4) 0.62    Intra-operative PaO2 (mmHg) 219.4 (11.2) 216.5 (16.8) 0.72 Values are expressed in absolute values or mean (SD). Abbreviations: TIVA-TCI total intravenous anaesthesia with target-controlled infusion, BAL balanced inhalation anaesthesia, LRP conventional laparoscopic radical prostatectomy, RALP robot-assisted laparoscopic prostatectomy. *According to Guidelines on Prostate Cancer, European Association of Urology, 2012. #Lymph node dissection was made in 45 out of 102 pts. During anaesthesia all patients received warm venous infusion of saline solution (0.9% NaCl) 3 ml Kg −1 h−1 and thermal mattresses. Systolic arterial pressure was maintained at 100 mm Hg or 70% of the preoperative value. Hypotension was treated with crystalloid NU7441 in vitro fluid infusion or intravenous boluses of ephedrine. After surgery the residual neuromuscular blockade was reversed with a mixture of atropine (Galenica Senese, Siena, Italy) 1.5 mg and neostigmine (IntrastigminaTM, Lusofarmaco, Milano, Italy) 2.5 mg. Anaesthetic agents were switched off, and 100% O2 was given with 8 l min fresh gas flow for 1 min. In addition, a forced-air warming blanket was used post-surgery (Equator Covective Warming TM, Smith Medical Italia, Milano,

Italy). After tracheal extubation all patients received ketoralac trometamina (Toradol, Recordati, Milano, check details Italy) 30 mg, ranitidine (RanidilTM, Menarini, Firenze, Italy) 50 mg and morphine (Recordati) 2 mg in bolus and then by

a controlled analgesia device (DeltecTM, Smiths Medical ASD, St Paul, MN). Clinical parameters The risk of venous thromboembolism was evaluated according to the model proposed by Caprini et al. [25] and Bergqvist et al. [26]. Patients were divided into 4 different levels of risk: low (score 0–1), moderate (score 2), high (score 3–4), highest (score >4). The following clinical parameters were also very evaluated: (a) global assessment of anesthetic risk (ASA), (b) grading of prostate cancer (Gleason score), (c) pathological tumor-node-metastasis stage, (d) time of surgery, (e) quantity and type of liquids administered, (f) blood loss, (g) peri-operative complications such as hypertension, hyperglycemia, hypothermia, infections and pain (evaluated by a 6-point verbal rating scale: 0: no pain to 5: most severe pain imaginable). In all patients, the presence of venous thrombosis by clinical observation, venous and pelvic ultrasound were evaluated in the peri-operative AZD2014 period and on days 8 and 21 after surgery. Prophylaxis anti-thrombosis Since in most of our patients changes in pro- and anti-coagulant and fibrinolytic markers were observed in the peri-operative period, an anti-thrombotic prophylaxis was made 24 hrs post surgery, for 4 weeks, by using Enoxaparina (ClexaneTM, Sanofi-Aventis, Milano) 4000 UI/die .